PRAX Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Praxis Precision Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.52 |
| 52 Week High | US$86.93 |
| 52 Week Low | US$19.61 |
| Beta | 2.69 |
| 1 Month Change | 3.85% |
| 3 Month Change | 24.40% |
| 1 Year Change | 275.84% |
| 3 Year Change | -75.25% |
| 5 Year Change | n/a |
| Change since IPO | -81.65% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation
Dec 13
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Shareholder Returns
| PRAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.0% | -5.6% | -3.5% |
| 1Y | 275.8% | -1.5% | 22.1% |
Return vs Industry: PRAX exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: PRAX exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| PRAX volatility | |
|---|---|
| PRAX Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRAX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Marcio De'Souza | praxismedicines.com |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
Praxis Precision Medicines, Inc. Fundamentals Summary
| PRAX fundamental statistics | |
|---|---|
| Market cap | US$1.36b |
| Earnings (TTM) | -US$151.02m |
| Revenue (TTM) | US$1.61m |
888.6x
P/S Ratio-9.4x
P/E RatioIs PRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRAX income statement (TTM) | |
|---|---|
| Revenue | US$1.61m |
| Cost of Revenue | US$114.51m |
| Gross Profit | -US$112.91m |
| Other Expenses | US$38.11m |
| Earnings | -US$151.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.10 |
| Gross Margin | -7,034.77% |
| Net Profit Margin | -9,409.22% |
| Debt/Equity Ratio | 0% |
How did PRAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Tazeen Ahmad | BofA Global Research |
| Joshua Schimmer | Evercore ISI |